title: Ovarian responses in Bos indicus heifers treated to synchronise ovulation with intravaginal progesterone releasing devices, oestradiol benzoate, prostaglandin F(2α) and equine chorionic gonadotrophin.
abstract: The objectives were: (i) improve understanding of the ovarian responses of Bos indicus heifers treated with different ovulation synchronisation protocols, (ii) compare ovarian responses of B. indicus heifers treated with intravaginal progesterone releasing device (IPRD)+oestradiol benzoate (ODB) versus a conventional prostaglandin F(2α) (PGF(2α)) protocol and (iii) investigate whether reducing the amount of progesterone (P(4)) in the IPRD, and treatment with equine chorionic gonadotrophin (eCG) would increase the proportion of heifers with normal ovarian function during the synchronised and return cycles. Two-year-old Brahman (n=30) and Brahman-cross (n=34) heifers were randomly allocated to three IPRD-treatment groups: (i) standard-dose IPRD (Cue-Mate(®) 1.56g P(4); n=17); (ii) half-dose IPRD (Cue-Mate(®) 0.78g P(4); n=15); (iii) half-dose IPRD+300IU eCG at IPRD removal (n=14), and a non-IPRD control group (iv) 2×PGF(2α) (500μg cloprostenol) on Days -16 and -2 (n=18). IPRD-treated heifers received 250μg cloprostenol at IPRD insertion (Day -10) and IPRD removal (Day -2) and 1mg ODB on Days -10 and -1. Ovarian function was evaluated by ultrasonography and plasma P(4) throughout the synchronised and return cycles. The mean diameter of the dominant follicle observed at 54-56h after IPRD removal, was greater for heifers which ovulated than heifers which did not ovulate (P<0.001; 14.5±1.1 vs. 9.3±0.6mm, respectively). The prevalence of IPRD-treated heifers with ovarian dysfunction (persistent CL, failure to re-ovulate, shortened luteal phase) was 39%. This relatively high prevalence of ovarian dysfunction may explain the commonly reported, lower than expected pregnancy rates to FTAI in B. indicus heifers treated to synchronise ovulation.
authors.affiliation: School of Veterinary Science, The University of Queensland, Gatton, Queensland, Australia. s.butler@uq.edu.au
authors.forename: S A A
authors.initials: SA
authors.lastname: Butler
authors.forename: N J
authors.initials: NJ
authors.lastname: Phillips
authors.forename: G B
authors.initials: GB
authors.lastname: Boe-Hansen
authors.forename: G A
authors.initials: GA
authors.lastname: Bo
authors.forename: B M
authors.initials: BM
authors.lastname: Burns
authors.forename: K
authors.initials: K
authors.lastname: Dawson
authors.forename: M R
authors.initials: MR
authors.lastname: McGowan
mesh_terms: D000282:Administration, Intravaginal; D000818:Animals; D002417:Cattle / Q000502:physiology*; D006063:Chorionic Gonadotropin / Q000008:administration & dosage*; D003008:Cloprostenol / Q000008:administration & dosage; D015237:Dinoprost / Q000008:administration & dosage*; D004958:Estradiol / Q000008:administration & dosage / Q000031:analogs & derivatives*; D004973:Estrus Synchronization / Q000187:drug effects*; D005260:Female; D006064:Gonadotropins, Equine / Q000008:administration & dosage*; D007315:Insemination, Artificial / Q000379:methods / Q000662:veterinary; D010053:Ovary / Q000187:drug effects; D010060:Ovulation / Q000187:drug effects*; D011374:Progesterone / Q000008:administration & dosage* / Q000097:blood
chemical_list: D006063:Chorionic Gonadotropin; D006064:Gonadotropins, Equine; C074283:estradiol 3-benzoate; D003008:Cloprostenol; D011374:Progesterone; D004958:Estradiol; D015237:Dinoprost